Last edition
News about "RATIONALE 302 trial of tislelizumab in patients wi"
Novartis announced results from the pivotal phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001). The study evaluated tislelizumab in patients with unresectable recurrent locally advanced
RATIONALE 302 Trial Of Tislelizumab In Patients Wi | 07/06/2021 | By Darshana | 394
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members